Leerink Swann Upgrades Thoratec (THOR) to Outperform; Encouraging Early Signs of Improving DT Market Growth
Tweet Send to a FriendGet Alerts THOR Hot Sheet
Price: $31.49 --0%
Rating Summary:
12 Buy, 13 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 6
Rating Summary:
12 Buy, 13 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 6
Trade THOR Now!
Leerink Swann upgraded Thoratec (NASDAQ: THOR) from Market Perform to Outperform.
Leerink analyst says, "Last week, we attended the ISHLT annual meeting and
left more encouraged that: 1) DT market growth---though likely gradual---should accelerate longer term, and 2) THOR may be better able to maintain BTT market share than investors had originally feared. We are upgrading THOR to Outperform, as we believe going forward investors will gain even more clarity on the size and ramp of the DT market and potential VAD market share shifts post-competitive launch. To us, the DT market represents a significant ~$2.5B+ market opportunity for THOR with no near-term competition. And while growth in this market has been slower than many investors had hoped or expected, physician commentary from ISHLT suggests that high-single-digit to low-double-digit market growth---at least---is sustainable."
For more ratings news on Thoratec click here and for the rating history of Thoratec click here.
Shares of Thoratec closed at $27.42 yesterday, with a 52 week range of $22.33-$47.93.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Leerink analyst says, "Last week, we attended the ISHLT annual meeting and
left more encouraged that: 1) DT market growth---though likely gradual---should accelerate longer term, and 2) THOR may be better able to maintain BTT market share than investors had originally feared. We are upgrading THOR to Outperform, as we believe going forward investors will gain even more clarity on the size and ramp of the DT market and potential VAD market share shifts post-competitive launch. To us, the DT market represents a significant ~$2.5B+ market opportunity for THOR with no near-term competition. And while growth in this market has been slower than many investors had hoped or expected, physician commentary from ISHLT suggests that high-single-digit to low-double-digit market growth---at least---is sustainable."
For more ratings news on Thoratec click here and for the rating history of Thoratec click here.
Shares of Thoratec closed at $27.42 yesterday, with a 52 week range of $22.33-$47.93.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Goldman Sachs Downgrades Thoratec (THOR) to Neutral
- Thoratec Announces FDA Approval Of HeartMate II® Pocket Controller™
- Goldman Sachs Upgrades Accenture plc (ACN) to Buy
Create E-mail Alert Related Categories
Hot Upgrades, Upgrades
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
